Melanotan II (MT-II) is a cyclic synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH), developed at the University of Arizona in the 1980s and 1990s by researchers seeking to understand the melanocortin receptor system and its potential therapeutic applications. Unlike its linear counterpart Melanotan I (afamelanotide), Melanotan II is a non-selective, pan-melanocortin receptor agonist — it binds with high affinity to MC1R, MC3R, MC4R, and MC5R — which gives it a broader biological profile than receptor-selective compounds and makes it a widely used research tool for studying the melanocortin system as a whole. This article reviews the published research on Melanotan II’s mechanisms, receptor interactions, and key areas of investigation. All content is presented for informational and research purposes only.

Molecular Profile

Melanotan II has the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂. Two key modifications distinguish it from native α-MSH: the replacement of methionine at position 4 with norleucine (Nle), and the substitution of L-phenylalanine at position 7 with D-phenylalanine (D-Phe). These changes confer dramatically enhanced receptor binding affinity and metabolic stability compared to the endogenous ligand. The cyclic structure (via an Asp-Lys lactam bridge) further rigidifies the peptide’s conformation, locking the pharmacophore into a receptor-optimized geometry.

The result is a peptide with substantially higher potency at melanocortin receptors than native α-MSH — roughly 100-fold more potent in some assays — and a longer half-life in biological systems.

Key Parameters: – Molecular formula: C₅₀H₆₉N₁₅O₉ – Molecular weight: ~1024.18 Da – CAS Number: 121062-08-6 – Receptor profile: non-selective agonist at MC1R, MC3R, MC4R, MC5R – Does NOT bind MC2R (the ACTH/cortisol receptor)

The Melanocortin Receptor System

To understand Melanotan II’s research profile, it is necessary to understand the receptor family it acts upon. The five melanocortin receptors (MC1R–MC5R) are G-protein-coupled receptors with distinct tissue distributions and functions:

• MC1R: Expressed primarily in skin melanocytes and immune cells; governs melanin pigment switching between eumelanin (dark/UV-absorbing) and pheomelanin (red/yellow); also expressed on macrophages and involved in anti-inflammatory signaling
• MC2R: Exclusive receptor for ACTH; mediates cortisol production in the adrenal gland; NOT bound by Melanotan II
• MC3R: Brain and periphery; involved in energy homeostasis, immune regulation, and inflammation
• MC4R: Predominantly in the hypothalamus and brainstem; the primary central mediator of appetite suppression, energy expenditure, sexual function, and body weight regulation
• MC5R: Ubiquitous; involved in exocrine gland secretion and immune function

Melanotan II’s non-selective binding across MC1R, MC3R, MC4R, and MC5R means that studies using this compound illuminate the melanocortin system’s integrated functions — making it invaluable as a research tool for understanding system-wide melanocortinergic biology (PMID: 5999398 via PMC).

Melanogenesis and MC1R Agonism

MC1R is the primary receptor governing eumelanin synthesis in skin melanocytes. When activated by α-MSH or synthetic agonists like Melanotan II, MC1R signals through cAMP/PKA pathways to upregulate MITF (microphthalmia-associated transcription factor), which in turn drives expression of melanogenic enzymes — most critically tyrosinase, the rate-limiting enzyme in melanin biosynthesis.

The resulting pigment shift is from pheomelanin (red/yellow, relatively poor UV protection) to eumelanin (dark brown/black, substantially better UV absorption across the spectrum). This shift has functional significance for photoprotection research: eumelanin-rich skin provides meaningfully greater UV protection than pheomelanin-dominant skin.

A landmark clinical study examined this mechanism directly, testing [Nle4, D-Phe7]-α-MSH (NDP-MSH, essentially the same modification pattern as Melanotan II’s key residues) in 77 Caucasian individuals stratified by MC1R genotype (PMID: 16293341). Results showed that MELANOTAN (NDP-MSH) significantly increased the eumelanin content of skin cells in individuals with MC1R variant alleles — specifically those individuals with reduced endogenous MC1R signaling capacity who are most at risk from UV radiation. This finding is directly relevant to research on photodamage prevention in high-risk populations.

Photoprotection Research

The photoprotective potential of MC1R-mediated melanogenesis has driven significant research interest in melanocortin agonists, particularly for individuals with fair skin, MC1R loss-of-function variants, or conditions associated with abnormal melanogenesis (such as vitiligo or erythropoietic protoporphyria — the condition for which Melanotan I/afamelanotide was ultimately approved in Europe and Australia).

The mechanistic argument for melanocortin agonist-mediated photoprotection is straightforward: by shifting the melanin phenotype toward eumelanin prior to UV exposure, the skin’s intrinsic UV-blocking capacity is enhanced. This is sometimes called “photoprotective tanning” to distinguish it from UV-induced tanning (which itself causes DNA damage during the tanning process).

Research with Melanotan II and related compounds in animal models has demonstrated that elevated eumelanin content reduces UV-induced thymine dimer formation in skin DNA — a direct measure of UV genotoxic damage. The translational implications for melanoma prevention research have attracted ongoing scientific interest, though this remains an active area of preclinical investigation.

Appetite Modulation and MC4R Research

Melanotan II’s potent MC4R agonism makes it one of the most-studied pharmacological tools in energy homeostasis research. MC4R is the dominant central receptor governing the balance between energy intake and energy expenditure; mutations that inactivate MC4R are the most common monogenic cause of human obesity.

Research by Raposinho et al. demonstrated that intracerebroventricular Melanotan II inhibits feeding, suppresses NPY’s orexigenic action, and reduces basal insulinaemia (PMID: 12535159). These effects represent pharmacological proof-of-concept for MC4R agonism as a strategy in obesity research.

A 2017 study by Zheng and colleagues characterized the long-term metabolic effects of continuous MTII-mediated central melanocortin activation, finding that chronic MC4R stimulation can reduce body mass persistently without requiring long-term caloric restriction (PMID: 28051332). This work highlighted both the power of MC4R signaling in body weight regulation and the complex adaptations that occur with sustained melanocortin system activation — including initial robust anorexia followed by partial tolerance and compensatory adjustments in energy expenditure.

These studies position Melanotan II as a key research tool for investigating the central melanocortin system’s role in obesity, metabolic syndrome, and related conditions.

Sexual Function Research and MC4R

Another prominent area of Melanotan II research involves its MC4R-mediated effects on sexual function. Hypothalamic MC4R signaling is involved in the regulation of erectile function and sexual motivation through downstream pathways involving oxytocin neurons and spinal cord erection centers.

A double-blind, placebo-controlled crossover study by Wessells et al. administered Melanotan II to men with both psychogenic and organic erectile dysfunction, documenting melanocortin receptor agonism as a mechanism capable of facilitating erectile responses in this patient population (PMID: 11035391). The findings were significant enough to spawn a subsequent class of MC4R-focused clinical development programs, including bremelanotide (PT-141), which gained FDA approval for hypoactive sexual desire disorder. A comprehensive review by Safarinejad summarized progress in melanocortin receptor agonist development for sexual dysfunction, covering melanotan I, melanotan II, and bremelanotide (PMID: 25096243).

Compound Information

• Chemical Name: Melanotan II ([Nle4, D-Phe7]-α-MSH, cyclic)
• Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂
• Molecular Weight: ~1024.18 Da
• Classification: Synthetic non-selective melanocortin receptor agonist
• CAS Number: 121062-08-6
• Receptor Binding: MC1R, MC3R, MC4R, MC5R (does not bind MC2R)
• Research Storage: Lyophilized powder; stable at −20°C; protect from light; reconstitute in sterile water or bacteriostatic water for research applications

References

1. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. PMID:16412534
2. Beaumont KA, Newton RA, Smit DJ, et al. Effect of MELANOTAN, [Nle4, D-Phe7]-alpha-MSH, on melanin synthesis in humans with MC1R variant alleles. Pigment Cell Res. 2005;18(5):345-351. PMID:16293341
3. Raposinho PD, White RB, Aubert ML. The melanocortin agonist Melanotan-II reduces the orexigenic and adipogenic effects of neuropeptide Y (NPY) but does not affect the NPY-driven suppressive effects on the gonadotropic and somatotropic axes in the male rat. J Neuroendocrinol. 2003;15(2):173-181. PMID:12535159
4. Wessells H, Fuciarelli K, Hansen J, et al. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res. 2000;12 Suppl 4:S74-79. PMID:11035391
5. Safarinejad MR. Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions: results from basic research and clinical studies. J Sex Med. 2014;11(8):1958-1976. PMID:25096243
6. Zheng H, Corkern M, Stornetta R, et al. Activation of the central melanocortin system chronically reduces body mass without the necessity of long-term caloric restriction. Am J Physiol Regul Integr Comp Physiol. 2017;312(1):R72-R79. PMID:28051332

Research Use Disclaimer: Melanotan II is sold by Rejuven8 Peptides strictly for in vitro and preclinical research use only. It is not intended for human consumption, veterinary use, or any therapeutic application. This content is educational and does not constitute medical advice. Always comply with applicable laws and institutional guidelines governing peptide research.

All products are sold for research purposes only. Not for human consumption. These statements have not been evaluated by the FDA. This content is for informational and educational purposes only and does not constitute medical advice.